文献速递艾滋病与性传播感染病毒性肝炎

HIV/HBV合并感染者替诺福韦治疗期间HBsAg清除者的循环HBV RNA与乙型肝炎核心相关抗原轨迹

Circulating HBV RNA and Hepatitis B Core-Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy.
PubMed 文献 · J Infect Dis · 2024-01-01

在瑞士HIV队列研究中,比较29例替诺福韦治疗期间HBsAg清除者与29例匹配无清除者的HBV RNA和HBcrAg轨迹。HBsAg清除者均在定量HBsAg转阴前出现HBV RNA抑制,HBV RNA下降≥1 log10 copies/mL对HBsAg清除敏感性100%但特异性仅36.4%。

要点

  • HBsAg清除者均先出现HBV DNA抑制和HBV RNA检测不到,再出现定量HBsAg检测不到。
  • 替诺福韦治疗2年时HBV RNA下降≥1 log10 copies/mL预测HBsAg清除敏感性100%、特异性36.4%。
  • HBsAg清除者中约20%HBcrAg仍可检测到,无清除者中约50%HBcrAg仍可检测到。

核心结论

  • 在HIV感染者替诺福韦治疗期间,HBV RNA抑制先于定量HBsAg检测不到出现,对HBsAg清除敏感性高但特异性低。
  • HBsAg清除者中约20%HBcrAg仍可检测到,无HBsAg清除者中约50%HBcrAg仍可检测到。

研究设计与样本

  • 瑞士HIV队列研究,纳入29例替诺福韦治疗期间HBsAg清除的HIV感染者和29例匹配的无HBsAg清除的HIV感染者。
  • 比较HBV RNA和HBcrAg下降轨迹,采用Kaplan-Meier法评估治疗期间HBV RNA和HBcrAg检测不到的累积比例。

主要发现

  • HBsAg清除发生在中位4年(IQR,1-8)时。
  • 所有HBsAg清除者均实现HBV DNA抑制和HBV RNA检测不到,且均发生在定量HBsAg检测不到之前,其中79%实现HBcrAg阴性。
  • 无HBsAg清除者中79%实现HBV RNA检测不到,48%实现HBcrAg阴性。
  • 替诺福韦治疗2年时,HBV RNA下降≥1 log10 copies/mL对HBsAg清除的敏感性为100%、特异性为36.4%。
  • 替诺福韦治疗2年时,HBcrAg下降≥1 log10 U/mL对HBsAg清除的敏感性为91.0%、特异性为64.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We evaluated long-term trajectories of circulating hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (HBcrAg) in persons with and without hepatitis B surface antigen (HBsAg) loss during tenofovir therapy in the Swiss HIV Cohort Study. METHODS: We included 29 persons with HIV with HBsAg loss and 29 matched persons with HIV without HBsAg loss. We compared HBV RNA and HBcrAg decline and assessed the cumulative proportions with undetectable HBV RNA and HBcrAg levels during tenofovir therapy using Kaplan-Meier estimates. RESULTS: HBsAg loss occurred after a median of 4 years (IQR, 1-8). All participants with HBsAg loss achieved suppressed HBV DNA and undetectable HBV RNA preceding undetectable quantitative HBsAg levels, whereas 79% achieved negative HBcrAg. In comparison, 79% of participants without HBsAg loss achieved undetectable HBV-RNA and 48% negative HBcrAg. After 2 years of tenofovir therapy, an HBV RNA decline ≥1 log10 copies/mL had 100% sensitivity and 36.4% specificity for HBsAg loss, whereas an HBcrAg decline ≥1 log10 U/mL had 91.0% sensitivity and 64.5% specificity. CONCLUSIONS: HBV RNA suppression preceded undetectable quantitative HBsAg levels and had high sensitivity but low specificity for HBsAg loss during tenofovir therapy in persons with HIV. HBcrAg remained detectable in approximately 20% of persons with HBsAg loss and 50% of persons without HBsAg loss.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Begré L, Boyd A, Plissonnier ML, et al. Circulating HBV RNA and Hepatitis B Core-Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy. J Infect Dis. 2024. PMID: 38626170. doi:10.1093/infdis/jiae189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。